Whole Network Most Recent TOP10 Entrepreneurship Innovation Private Equity Venture Capital

 

China, US Ink Deal on Some Drugs

Filed in archive Law by Greg Cruey on December 13, 2007

China and the U.S. signed an agreement Tuesday that could improve the safety of some commonly used drugs in the U.S., including Lipitor, Viagra, a flu drug called oseltamivir, and an antibiotic used for eye infections called gentamicin sulfate.

A recent Associated Press story notes that "The global pharmaceutical industry increasingly uses drugs either made or containing ingredients sourced in China."

37741961.jpg


The agreement was one of several signed as part of the Joint Commission on Commerce and Trade (JCCT)meeting that just ended. The JCCT meets twice each year. The agreement, according the Forbes, will see China register producers of drugs and medical devices and "ensure they meet US safety standards and notify the US when safety problems surface."

While the new agreement may be a small step in the right direction, healthcare blogger Barbara Duck points out that "the accord covers only a tiny fraction of the pharmaceutical ingredients being marketed worldwide by thousands of unlicensed chemical companies. "

Another Blogosphere resident, Ellroon, was more cynical: "This should last about two minutes.... "

Under the agreement, U.S. food and drug inspectors will gain increased access to Chinese facilities where the drugs in questions are actually being produced. A working group of U.S. and Chinese officials is supposed to meet with 120 days to develop a plan to implement the new agreement.


Advertisement


Permalink: China, US Ink Deal on Some Drugs
Tags: drugs  china  atorvastatin  Lipitor  sildenafil  Viagra  antibiotic  gentamicin  oseltamivir  flu  2007  decemb 

Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/106575



Advertisement


Advertisement


CW ToolbarInstall
RSSrss   | See all blog subscribe options
Googlegoogle   |   What is RSS?
Yahoo!yahoo
AddthisAddThis Feed Button
BloglinesBloglines
Newsletter
Advertisement - Book yours here.

Use our search feature to look for other interesting posts

Just this blog Whole network
  • ChinaVentureNews seeks news contributions



    If you are an analyst, tech company, private equity firm, service provider or entrepreneur with news to share related to China venture capital send us your relevant news release.

    CVN will post it to our site. We reserve the right to edit the copy because of space limitations, and to make summaries of the release when appropriate-- although a full copy of the release will always be linked to.

    Thank you!

    Please simply use our form here.
Advertisement -
Book yours here..


 
  • Would you like to have a new interactive marketing channel for your company? Learn more about Sponsored Blogs with Creative Weblogging. See how we helped companies like Weblin and cellity reach their goals.
  • Would you like to reach millions of blog readers every day? See you banner on hundreds of blogs with TierOneAds? Stay in control measuring conversion in real time. Register now.
  • Would you like to make more money blogging? Use TierOneAds a new platform that allows you as a blogger to set your prices per impression. Register now.
  • Do you have a blog with more than 50k page views from the US? Let us market your blog and earn great fix payments and bonuses.
  • Would you like to see your text link here? Let us know!
Advertisement
Book yours here.



  • Testimonials

  • 'Exactly what I am looking for.'

    "One of my favorite blogs."
  • Other blogs in the same channel in the Creative Weblogging Network

Advertisement -
Book yours here..






Advertisement - Book yours here..
 
Tagcloud: Agreement Blogs Book review Commodities Conferences Entrepreneurship Incubators and Science Parks Information Sources Innovation Internet IPOs Law M&A Mergers and Acquisitions News Outsourcing Policy Private Equity Sovereign Wealth Funds Sponsored Post Stocks Studies Technology Report Treatment VC and PE: education and training Venture Capital Yuan Renminbi